|
Globally
Novo Nordisk has invested in establishing the Oxford Center for Diabetes, Endocrinology and Metabolism. The Company has partnered with the University of Oxford and the World Health Organization to create the Oxford Vision 2020 process. In addition, we are developing research initiatives with the European Association for the Study of Diabetes and the Juvenile Diabetes Research Foundation International. In 2001, Novo Nordisk established the World Diabetes Foundation. Most recently, it was announced that Novo Nordisk will be the only pharmaceutical company, together with approximately 100 scientists from all over Europe, to participate in the agreement between The European Commission and the Technical University of Denmark on 'Biosimulation - A New Tool in Drug Development' under the European Union's Sixth Framework Programme for Research.
Vist the Novo Nordisk Global Partnering site.
|